Treatment of pancreatic neuroendocrine tumors with Ang2 and VEGFR-2 blockers decreased Tie2 monocyte infiltration and suppressed revascularization and tumor progression [133], prompting next-generation anti-angiogenesis (Figure 2) [22,102,134]. The gene discussed is KDR; the disease is neoplasm.